Please login to the form below

Not currently logged in
Email:
Password:

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

Takeda HQJapanese pharma company Takeda has signed a deal potentially worth $230m with ImmunoGen for two anticancer targets.

Specifically, Takeda has licensed exclusive rights to use ImmunoGen's ADC technology -including ImmunoGen's new DNA-acting IGN payload agents - to develop and commercialise targeted anticancer therapeutics to up to two undisclosed targets. 

The agreement also provides Takeda, which signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals, with the option to take a license for a third target for an additional upfront fee.

Daniel Junius, ImmunoGen's president and CEO, said: “Takeda shares our commitment to developing novel anticancer therapies that meaningfully improve the lives of patients, and we look forward to collaborating with them to create important new ADC product candidates.

ImmunoGen will receive $20m upfront and for each target is eligible to receive milestone payments potentially reaching $210m, plus royalties, on the sales of any resulting ADC products. 

Takeda will then be responsible for the development, manufacturing and marketing of any ADC products resulting from the agreement.

Christopher Claiborne, head of the oncology drug discovery unit at Takeda, said: “ADC technology is a critically important tool in addressing unmet needs in oncology. By partnering with ImmunoGen, we are able to leverage this important technology in Takeda's R&D program and bring novel agents through the clinic.”

Big pharma has already benefited from using ImmunoGen's platform, with its tubulin-acting maytansinoids being used in over ten ADCs, and most notably was used to create Roche's breast cancer drug Kadcyla (trastuzumab emtansine).

Article by
Ben Adams

24th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...